Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.21 | -0.04 | 0.07 |
| FCF Yield | -17.44% | -42.42% | -58.74% | -21.58% |
| EV / EBITDA | -2.58 | -1.16 | -0.58 | -2.26 |
| Quality | ||||
| ROIC | -25.75% | -33.29% | -27.88% | -22.17% |
| Gross Margin | 93.46% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.97 | 0.83 | 1.07 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,189,659.57% | 1,912,831.18% | 1,912,831.18% | 1,912,831.18% |
| Free Cash Flow Growth | 26.75% | 23.87% | -64.82% | 23.98% |
| Safety | ||||
| Net Debt / EBITDA | 1.54 | 0.25 | 0.65 | -0.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -536.40 | 0.00 | 0.00 | 0.00 |